Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application

NANot yet recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
CancerSolid Tumor CancerChemotherapy
Interventions
BEHAVIORAL

Mobile Symptom Monitoring and Alert App

Responses to the PRO-CTCAE questions range from 0-4. Any grade 1 response (reflecting mild symptoms) will trigger symptom management/education tips to be shown (which are also available to view anytime in a self-care library in the app), and any grade 2-4 response (reflecting moderate to severe symptoms) will trigger a recommendation that the participant may want to contact their provider about the potentially concerning symptom. Fitbit data points exceeding prespecified thresholds based on physiological norms (for skin temperature and pulse oxygenation) or each participants' historic average (heart rate and activity) will trigger follow-up questions and, depending on responses, also a recommendation that the participant may want to contact their provider about the potentially concerning data point. Participants will be able to generate data reports from within the ROSA app that show summaries/graphs of recent alerts triggered, symptom ratings, and Fitbit data.

Trial Locations (1)

15232

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Pittsburgh

OTHER

NCT07218874 - Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application | Biotech Hunter | Biotech Hunter